Geographic atrophy (GA) affects around 5 million individuals worldwide. Genome-wide,
histopathologic, in vitro and animal studies have implicated the activation of the complement …

Regulatory approval of the first two therapeutic substances for the management of
geographic atrophy (GA) secondary to age-related macular degeneration (AMD) is a major …

Purpose To quantify morphological changes of the photoreceptors (PRs) and retinal pigment
epithelium (RPE) layers under pegcetacoplan therapy in geographic atrophy (GA) using …

Geographic atrophy (GA) represents a late stage of age-related macular degeneration,
which leads to irreversible vision loss. With the first successful therapeutic approach, namely …

The use of optical attenuation coefficients (OAC) in optical coherence tomography (OCT)
imaging of the retina has improved the segmentation of anatomic layers compared with …

Age-related macular degeneration (AMD) is a leading cause of severe vision loss
worldwide, with a global prevalence that is predicted to substantially increase. Identifying …

Age‐related macular degeneration is a global disease with a significant societal impact. The
advent of anti‐vascular endothelial growth factor therapy (anti‐VEGF) has revolutionised the …

Current Opinion in Ophthalmology Log in or Register Subscribe to journalSubscribe Get new
issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …

It is likely that current clinical practice will need to change following the application of AI-
enabled medical devices. These devices are likely to have an impact on the management of …

Purpose Nascent geographic atrophy (nGA) refers to specific features seen on OCT B-
scans, which are strongly associated with the future development of geographic atrophy …